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Abstract
Pancreatic neuroendocrine tumors (NET) have diverse clinical presentations. Patients with symptoms of hormone
secretion may require specific medical interventions to control those symptoms prior to antitumor intervention.
In some patients, tumors in the pancreas may be occult and specialized diagnostic imaging or surgery may be
required for diagnosis. Other patients may present with more advanced disease, presenting with symptoms of
tumor bulk rather than hormone secretion. Treatment options for patients with advanced pancreatic
neuroendocrine tumors include surgical resection and hepatic directed therapies, including partial hepatectomy,
hepatic artery embolization, or other ablative techniques. Streptozocin or temozolomide-based chemotherapy
regimens are active against pancreatic NET, and can also play an important role in the palliation of patients with
advanced disease. A number of biologically targeted agents targeting the VEGF and mTOR signaling pathways
have recently shown promise, with recent trials showing treatment with the VEGFR tyrosine kinase inhibitor
sunitinib or the mTOR inhibitor everolimus improves progression-free survival in patients with advanced NET.
Introduction
Pancreatic neuroendocrine tumors (NET) have been
considered rare, with an estimated incidence of less
than 1 per 100,000 individuals [1]. In recent years, how-
ever, the diagnosed incidence of pancreatic NET has
increased, an observation that is likely due, at least in
part, to improved detection and classification [2]. The
diverse and sometimes non-specific clinical syndromes
associated with pancreatic NET can make these malig-
nancies difficult to diagnose at an early stage. Awareness
of the clinical presentation and treatment options for
patients with pancreatic NET has become increasingly
relevant for both medical oncologists and other health
care providers, as new treatment options emerge for
patients with this disease.
Histologic Classification and Staging
Pancreatic NET have also been referred to as pancreatic
islet cell tumors or pancreatic endocrine tumors. Carci-
noid tumors have a similar histologic appearance to
pancreatic NET, but generally arise in the bronchi, small
intestine, appendix, or rectum. While the term “pancrea-
tic carcinoid” has also sometimes been used to describe
pancreatic NET, this term is considered confusing as
the clinical presentation and treatment options for pan-
creatic NET differ in many respects from those for car-
cinoid tumors.
The majority of pancreatic NET occur sporadically.
However, pancreatic NET can be associated with inherited
genetic syndromes; in particular, approximately 10% may
be associated with multiple endocrine neoplasia type 1
(MEN1). MEN1 is an autosomal dominant syndrome
associated with mutations in the tumor suppressor gene
menin, and is characterized by the development of
multiple NET involving not only the pancreas but also the
parathyroid and pituitary glands [3]. Pancreatic NET have
also been associated with MEN2, Von Hippel-Lindau
disease, tuberous sclerosis, and neurofibromatosis.
The histologic features of pancreatic NET can vary,
affecting both prognosis and treatment recommenda-
tions. An important first step following the diagnosis of a
pancreatic malignancy is the differentiation of neuroen-
docrine cancers from the far more common pancreatic
adenocarcinoma. Though the pathologic criteria for dif-
ferentiating these two entities are clear, limited tissue
from fine needle aspirations or endoscopic brushings
may preclude accurate diagnosis. In questionable cases,
repeat tissue sampling should be performed, particularly
if systemic treatments are being considered.
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tiating the various subtypes of pancreatic NET. These
tumors may fall within a broad spectrum of well-differ-
entiated, low grade tumors to more poorly differen-
tiated, high grade tumors. While a number of histologic
classification systems have been proposed for pancreatic
NET, tumors with a mitotic count >20/10 high powered
fields or a Ki-67 proliferation index of >20% generally
represent highly aggressive malignancies where treat-
ment with platinum based regimens is generally indi-
cated, according to small cell carcinoma guidelines [4,5].
The American Joint Committee on Cancer (AJCC) sta-
ging system for pancreatic NET is increasingly accepted as
the standard staging system in North America, and is simi-
lar to the system used for pancreatic adenocarcinomas.
Several other organizations, including both North-Ameri-
can based groups and the European Neuroendocrine
Tumor Society (ENETs) have proposed similar, though not
identical, staging systems for NET using the commonly
accepted Tumor Node Metastasis (TNM) notation [6-10].
Clinical Presentation and Initial Management
Most pancreatic NET are considered “non-functional” in
that they are not associated with symptoms of hormone
hypersecretion. Such tumors are usually identified inci-
dentally during imaging for other indications, or at an
advanced stage, when patients become symptomatic
from tumor bulk. Patients with hormonal hypersecre-
tion, on the other hand, can present with diverse and
sometimes puzzling clinical symptoms (Table 1). Speci-
fic recommendations for some of the more common
tumors, based on the clinical presentation and hor-
mones secreted, are described below.
Insulinoma
Insulinomas classically present with “Whipple’s Triad:” a
combination of symptoms of hypoglycemia, inappropriately
high insulin levels with associated documented blood glu-
cose levels of <50 mg/dL, and symptom relief with admin-
istration of glucose [11]. Initially, the hypoglycemia may be
managed with dietary modifications or with diazoxide [12].
For these patients, octreotide or other somatostatin analogs
should be used with caution, as they have the potential to
worsen hypoglycemia by suppressing glucagon secretion.
Treatment with the mTOR inhibitor everolimus has also
been reported to be beneficial in insulinoma patients with
refractory hypoglycemia [13].
Glucagonoma
Over two-thirds of patients with glucagonomas present
with necrolytic migratory erythema, a rash characterized
by raised erythematous patches beginning in the peri-
neum and progressing to the trunk and extremities
[14,15]. Somatostatin analogs are generally successful in
the initial management of patients with the glucago-
noma syndrome [16,17]. Glucagonomas may be asso-
ciated with diabetes mellitus, though only half of
patients experience clinically significant hyperglycemia.
Gastrinoma and Zollinger-Ellison syndrome
The gastrinoma syndrome is characterized by gastric
hypersecretion [18]. In patients with non-healing pep-
tic ulcers and a fasting gastrin level >100 pg/mL, a
diagnosis of gastrinoma should be considered [19].
Moderate elevations of serum gastrin may also, how-
ever, be seen in patients receiving concomitant therapy
with proton pump inhibitors, sometimes complicating
efforts to confirm a diagnosis. Proton pump inhibitors
are a highly effective initial treatment in controlling
symptoms associated with gastric hypersecretion
[20,21]. Treatment with somatostatin analogs has also
been associated with improved control of serum gas-
trin levels and, in some cases, with tumor stabilization
or regression [22].
Table 1 Clinical presentation of pancreatic neuroendocrine tumors (NET)
Tumor Symptoms or signs Incidence
of
metastases
Extrapancreatic
location
Insulinoma Hypoglycemia resulting in intermittent confusion, sweating, weakness, nausea; loss of
consciousness may occur in severe cases
<15% Rare
Glucagonoma Rash (necrotizing migratory erythema), cachexia, diabetes, deep venous thrombosis Majority Rare
VIPoma,
Verner-Morrison
Syndrome,
WDHA Syndrome
Profound secretory diarrhea, electrolyte disturbances Majority 10%
Gastrinoma,
Zollinger-Ellison
Syndrome
Acid hypersecretion resulting in refractory peptic ulcer disease, abdominal pain, and diarrhea <50% Frequently in
duodenum
Somatostatinoma Diabetes, diarrhea, cholelithiasis Majority Rare
Non-functioning May be first diagnosed due to mass effect Majority Rare
WDHA: Watery Diarrhea, Hypokalemia and Achlorhydria.
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Pancreatic endocrine tumors associated with profound
diarrhea, hypokalemia, and achlorhydria were first
described by Verner and Morrison in 1958 [23]. This
syndrome was subsequently found to be due to ectopic
vasoactive intestinal peptide (VIP) secretion. Treatment
with somatostatin analogs is effective in treatment of
diarrhea in these patients [24].
Imaging
Patients with functioning tumors, particularly insulino-
mas and gastrinomas, may develop hormonal symptoms
from small primary tumors, and localization of the pri-
mary lesions may be challenging. Traditional cross-sec-
tional imaging with triple phase CT or MRI is generally
the first step in attempting to localize these tumors.
Endoscopic ultrasound may be more sensitive than CT
or MRI for the detection of small lesions, and may also
provide useful information regarding potential vessel
involvement prior to planned resection. Pancreatic NET,
like carcinoid tumors, frequently over express somatos-
tatin receptors.
111Indium-DTPA-octreotide (Octreos-
can™) has been commonly used, often in combination
with cross-sectional imaging, to localize and stage pan-
creatic NET.
Biochemical Assessment and Monitoring
In patients with symptoms of hormone hypersecretion,
serial measurements of the specific hormone may be
helpful in assessing treatment response or in monitoring
for recurrence. The majority of patients with pancreatic
NET, however, do not have clear evidence of hormone
hypersecretion. Serum chromogranin A (CGA) is a neu-
roendocrine secretory protein that serves as a marker of
disease activity in both functional and non-functional
pancreatic NET [1,25-27]. CGA may decrease in patients
responding to somatostatin analogs or other therapies
[26,28]. In patients on stable SSA doses, consistent
increases in plasma CGA levels over time may reflect
loss of secretory control and/or tumor growth
[25-27,29,30]. Use of CGA as ad i a g n o s t i co rs c r e e n i n g
test for pancreatic NET is discouraged, as CGA may be
elevated in a number of non-malignant conditions,
including renal insufficiency and liver disease, and in
patients taking proton pump inhibitors.
Surgical Management
In general, in the absence of distant metastases or signif-
icant comorbidities, complete surgical resection of the
primary tumor should be attempted [31,32]. The pri-
mary tumors in patients who are diagnosed due to
symptoms of hormone hypersecretion may be occult
(Figure 1A). In contrast, patients with non-functioning
pancreatic NET are commonly diagnosed at a later stage
(Figure 1B). The prognosis following surgical resection
of localized NET is often excellent. Isolated insulinomas,
for example, are generally treated with enucleation;
long-term survival following surgery in this patient
population exceeds 90% [33]. The role of surgical resec-
tion in patients with MEN1 syndrome remains more
controversial because of the risk of additional tumors
within the remaining pancreas and elsewhere [34,35].
In contrast to patients with pancreatic adenocarci-
noma, hepatic resection may be beneficial in patients
with metastatic pancreatic NET. Resection may be
Figure 1 Variations in size of primary pancreatic NET.
A: Insulinoma presenting as an occult nodule on the pancreas.
Functional pancreatic NET may present at an early stage, and
identification of the primary tumor may be challenging. B.
Non-functioning pancreatic NET in the tail of the pancreas with
associated hepatic metastases. Non-functioning pancreatic NET
more typically present at a later stage, often as bulky lesions in the
tail of the pancreas with associated liver metastases.
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ease and to diminish systemic symptoms. Hepatic resec-
tion is generally favored in patients with limited hepatic
disease. In a study of 170 patients, hepatic resection
improved symptoms in over 90% of cases [36]. Debulk-
ing surgery in patients with more advanced disease may
be recommended in selected patients if the majority (i.
e., >90%) of the tumor burden can be resected [37]. The
median survival for patients treated with this approach
has been reported to be 7 years [38]. The reported sur-
vival rates for this surgical approach have been in excess
of 60% at 5 years, which is twice that of patients with
untreated liver metastases [38,39]. An important obser-
vation is that the survival of patients who have palliative
hepatic debulking by 90% is indistinguishable from
those who have complete resection (i.e., resection of all
visible hepatic tumors) [39]. Also, the survival with this
approach is the same among patients with functional
and non-functional tumors [39]. Thus, surgical resection
should be considered to potentially improve outcomes
even though surgery may not be curative.
Liver-directed Therapy
In patients with hepatic metastases who are not candi-
dates for surgical resection, hepatic arterial embolization
may be an appropriate palliative technique, provided
that their disease is primarily confined to the liver, the
portal vein is patent, they have not undergone a Whip-
ple procedure (or pancreaticoduodenectomy), and that
patients have an otherwise preserved performance status
[40-42]. Response rates are generally >50%, whether
measured by reduced hormone secretion or radiographic
regression [40-43]. A variety of techniques have been
employed, including bland embolization, chemo-emboli-
zation, embolization with chemotherapy eluting beads,
or embolization using radioisotopes. There are currently
no data confirming superiority of any one of these tech-
niques over the others.
Hepatic metastases can also be treated with percuta-
neous or laparoscopic radiofrequency ablation (RFA)
and cryoablation, either alone or in conjunction with
surgical debulking [40,42]. While these approaches
appear to cause less morbidity than either hepatic resec-
tion or hepatic artery embolization, the clinical benefit
of this approach in patients with asymptomatic, small-
volume disease has not been clearly established. Ablative
techniques should be considered only in carefully
selected patients [40,42,44,45].
Cytotoxic Chemotherapy
Although carcinoid and pancreatic NET appear histolo-
gically similar, there is increasing evidence that pancrea-
t i cN E Ta r em o r er e s p o n s i v et oc h e m o t h e r a p yt h a na r e
carcinoid tumors (Table 2). In an initial randomized
trial, the combination of streptozocin and doxorubicin
was associated with a combined biochemical and radi-
ologic regression of 69%, as well as a survival benefit
when compared to streptozocin and fluorouracil [46].
The median overall survival duration for patients treated
with streptozocin and doxorubicin was 2.2 years. Strep-
tozocin was subsequently approved by the FDA as a
treatment for patients with pancreatic NET. The very
high response rates reported in this study were derived
in part from the historical use of non-standard response
criteria. A large retrospective analysis of 84 patients
with either locally advanced or metastatic pancreatic
endocrine tumors showed that a three-drug regimen of
streptozocin, 5-FU, and doxorubicin was associated with
an overall response rate of 39% and a median survival
duration of 37 months [47].
Despite the demonstrated efficacy of streptozocin-
based regimens, their potential toxicity, together with a
cumbersome 5 consecutive day infusion schedule, has
precluded their more widespread use in patients with
advanced pancreatic NET. Recent prospective and retro-
spective studies have suggested that oral temozolomide-
based regimens may be at least comparable in efficacy
to streptozocin-based regimens, and may also be more
tolerable. In retrospective series, temozolomide-based
therapy has been associated with overall response rates
of 8-70% [48-50] (Table 2). Temozolomide has been
evaluated prospectively in combination with thalido-
mide, bevacizumab, or everolimus, with overall response
rates of 24-45% [51-53]. Neither the optimal dosing
regimen for temozolomide, nor the relative activity of
temozolomide as a single agent or in combination with
other therapeutic agents has been clearly established.
Somatostatin Analogs and Peptide Receptor
Radiation Therapy (PRRT)
More than 90% of NET express somatostatin receptors,
and somatostatin analogs (SSAs) have been shown to be
effective in reducing symptoms of hormone hypersecre-
tion associated with both carcinoid and pancreatic NET.
In patients with midgut carcinoid tumors, treatment
with the somatostatin analog octreotide has been shown
to improve time to tumor progression over placebo.
Ongoing studies are currently exploring whether soma-
tostatin analogs have a similar antiproliferative effect in
patients with pancreatic NET.
The high rate of somatostatin receptor expression in
pancreatic NET also provides a rationale for peptide
receptor radionuclide therapy in patients with inoper-
able or metastatic disease. The most frequently used
radionucleotides for targeted radiotherapy in NET are
yttrium (
90Y), and lutetium (
177Lu), which differ from
one another in terms of emitted particles, particle
energy, and tissue penetration[54,55]. Both the yttrium
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promising activity in NET patients. The radiolabeled
somatostatin analog [
177Lu-DOTA, Tyr
3] octreotate, for
example, has been utilized in the treatment of 504
patients with NET, and efficacy results, reported for 310
patients, suggest single agent activity [56]. Treatment
with
90Y-DOTA tyr3-octreotide (
90Y-edotreotide) was
recently reported to be associated with high rates of
symptom control, though only modest tumor response
rates, in a prospective, phase II study [57]. Randomized
studies comparing PRRT to treatment with “cold”
octreotide are anticipated to better define the relative
efficacy and toxicities associated with these regimens.
Biologically Targeted Therapies for Pancreatic
NET
Studies of biologically targeted therapies in pancreatic
NET have, to date, focused primarily on inhibitors of
the VEGF or mTOR signaling pathways. While objective
RECIST-defined tumor response rates have been rela-
tively low, recent studies have suggested that treatment
with these agents is associated with improvements in
progression-free survival.
VEGF pathway inhibitors
Three tyrosine kinase inhibitors–pazopanib, sorafenib,
and sunitinib–all with activity against VEGFR, have
been evaluated in prospective trials of patients with
advanced pancreatic NET. Pazopanib was evaluated in a
prospective study enrolling 51 NET patients (29 with
pancreatic NET and 22 with carcinoid) on stable doses
of octreotide-LAR. Patients received pazopanib at a dose
of 800 mg daily. The response rate among patients with
pancreatic NET was 17%; no patients with carcinoid
experienced a radiographic response (by RECIST) [58].
Sorafenib is another small molecule tyrosine kinase inhi-
bitor with activity against VEGFR. In a study of 50
patients with carcinoid and 43 patients with pancreatic
NET, preliminary analysis showed responses in 7% of
the carcinoid patients and 11% of the pancreatic NET
patients [59].
Sunitinib malate was evaluated in a multi-institutional
phase II study enrolling 109 patients with advanced
NET. Patients received repeated 6-week treatment cycles
of sunitinib, administered orally at 50 mg once daily for
4 weeks, followed by 2 weeks off treatment [60]. Partial
responses were observed in 2% of the carcinoid cohort
Table 2 Selected Trials of Cytotoxic Chemotherapy in Advanced Pancreatic NET
Regimen Patients Tumor Response Rate
(%)
Median Progression- Free
Survival
Median Overall Survival
(Months)
Reference
Prospective
Studies
Chlorozotocin 33 30 17* 18.0 Moertel et al. 1992 [46]
Fluorouracil +
Streptozocin
33 45 14* 16.8 Moertel et al. 1992
Doxorubicin +
Streptozocin
36 69 18* 26.4 Moertel et al. 1992
DTIC 50 34 NR 19.3 Ramanathan et al. 2001
[67]
Temozolomide+
Thalidomide
11 45 NR NR Kulke et al. 2006 [52]
Temozolomide+
Bevacizumab
17 24 8.6 NR Kulke et al. 2006 [51]
Temozolomide+
Everolimus
24 35 NR NR Kulke et al. 2010 [53]
Retrospective
Studies
Steptozocin+
Doxorubicin+
Fluorouracil
84 39 18 37 Kouvaraki et al. 2004
[47]
Temozolomide
(diverse regimens)
53 34 13.6 35.3 Kulke et al. 2009 [49]
Temozolomide
(single agent)
12 8 NR NR Ekeblad et al. 2007 [48]
Temozolomide+
Capecitabine
30 70 18 NR Strosberg et al. 2010
[50]
NR: Not reported.
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dence of activity in this study, an international rando-
mized phase III study to confirm the activity of
sunitinib in pancreatic NET was undertaken. The study
was discontinued prior to a planned interim analysis
after enrollment of 171 patients, 86 of whom received
sunitinib and 85 of whom received placebo. The early
discontinuation of the study precluded definitive
hypothesis testing for differences in progression-free
survival durations between the treatment and placebo
groups. Nevertheless, analysis of the available data
demonstrated that treatment with sunitinib was asso-
ciated with a median progression-free survival (PFS) of
11.4 months, as compared with 5.5 months for placebo
(P=.0001, Table 3) [61].
mTOR Inhibitors
Tumor cell growth, proliferation, and apoptosis are regu-
lated in part by a serine-threonine kinase called the
mammalian target of rapamycin (mTOR). This enzyme
also mediates downstream signaling from a number of
pathways, including the VEGF and insulin-like growth
factor (IGF) signaling implicated in NET growth. Temsir-
olimus and everolimus are rapamycin derivatives that
have been evaluated recently in NET. Weekly intrave-
nous administration of temsirolimus was associated with
ar e s p o n s er a t eo f5 . 6 %i no n es t u d yo f3 7p a t i e n t sw i t h
advanced progressive NET. Outcomes were similar
between patients with carcinoid and pancreatic NET [62].
Everolimus was initially evaluated in a single-institu-
tion study, in which 30 patients with carcinoid tumors
and 30 with pancreatic NET received doses of 5 or 10
mg daily plus depot octreotide (30 mg every 4 weeks).
The overall tumor response rate in evaluable patients
was 17% in carcinoid and 27% in pancreatic NET [63].
A follow-up multinational phase II study (RADIANT-1)
enrolled 160 patients with advanced pancreatic NET
and evidence of RECIST-defined progression following
chemotherapy. In this non-randomized study, treatment
with everolimus was associated with an overall response
rate of 4.4% and progression-free survival duration of
16.7 months in those patients receiving octreotide.
Among patients not receiving octreotide, the response
rate was 9.6% and the progression-free survival duration
was 9.7 months [64]. A subsequent phase III study ran-
domized 410 patients with progressive advanced pan-
creatic NET (RADIANT-3) to receive treatment with
everolimus or placebo; octreotide was given at the dis-
cretion of the investigator. This study demonstrated sig-
nificant improvements in the primary endpoint of
investigator-assess PFS associated with everolimus as
compared to placebo (11 months versus 4.6 months, [P
<.0001, Table 3]) [65]. The overall tumor response rate
associated with everolimus in this study was 5%.
Ongoing studies are currently evaluating combinations
of targeted agents in patients with advanced pancreatic
NET. A combination of the mTOR inhibitor everolimus
and the VEGF inhibitor bevacizumab was recently
shown to be well tolerated and associated with antitu-
mor activity (overall response rate 26%) in an initial
phase II study enrolling patients with low or intermedi-
ate grade NET [66]. CALGB 80701 is currently rando-
mizing patients with advanced pancreatic NET to
receive either treatment with everolimus or everolimus
+ bevacizumab to assess the relative efficacy and toxicity
of these regimens (Table 3).
Conclusions
Patients with pancreatic NET present with diverse symp-
toms related to hormonal hypersecretion, tumor bulk, or
both. Accurate diagnosis of this condition and differentia-
tion of pancreatic NET from the more common pancreatic
adenocarcinomas is a critical first step in developing an
appropriate treatment plan. Similarly, pancreatic NET
should be considered separately from carcinoid tumors,
which arise in other sites. Surgical resection remains the
mainstay of treatment for patients with localized disease.
A number of treatment options are available for patients
with advanced pancreatic NET. These include hepatic-
directed therapies, including surgical resection and hepatic
artery embolization. Systemic treatment options include
the use of SSAs for control of hormonal hypersecretion, as
well as alkylating chemotherapy. Recent studies have also
reported that the tyrosine kinase inhibitor sunitinib and
the mTOR inhibitor everolimus improved progression-
free survival in patients with pancreatic NET, further
Table 3 Randomized Trials of Biologically Targeted Therapies in Pancreatic NET
Regimen N
(total)
Overall
Response Rate
Median Progression-Free
Survival/TTP
P
value
Reference
Sunitinib (37.5 mg po qd)
Placebo (+ best supportive care)
171 9%
0%
11.4 months
5.5 months
.0001 Raymond et al,
2011 [61]
Everolimus (10 mg po qd)
Placebo (+ best supportive care)
410 5%
2%
11 months
4.6 months
<.0001 Yao et al, 2011
[65]
Everolimus (10 mg po qd)
Everolimus (10 mg po qd) + Bevacizumab (10 mg/kg
every other week)
CALGB
80701
(Ongoing)
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with this disease. Future studies will likely build on these
results, further improving therapeutic options for patients
with this disease.
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